Helus Pharma reports positive Phase III HLP003 results in major depressive disorder

Helus Pharma has reported positive Phase III results for investigational deuterated psilocin treatment HLP003 in major depressive disorder, with statistically significant improvements in depression scores through 12 weeks.
Helus Pharma announced on 16 November 2026 that its Phase III APPROACH study evaluating HLP003, a deuterated psilocin-based investigational medicine, as adjunctive treatment for major depressive disorder had met its primary and key secondary endpoints in a trial involving 222 participants.
At week six, the company reported a 7.6-point placebo-adjusted improvement in Montgomery–Åsberg Depression Rating Scale score with statistical significance at p<0.0001, alongside a 7.0-point placebo-adjusted difference at week 12 and treatment effects observed as early as day two; three treatment-related serious adverse events were reported, and the results remain company-reported topline findings rather than evidence of regulatory approval.
Field | Content |
Article Type | Industry Updates |
Company | Helus Pharma |
Investigational Medicine | HLP003 |
Active Compound Description | Deuterated psilocin |
Development Stage | Phase III |
Clinical Trial | APPROACH |
Announcement Date | 16 November 2026 |
Therapeutic Area | Psychiatry |
Indication | Major depressive disorder |
Treatment Setting | Adjunctive treatment |
Trial Participants | 222 |
Primary Endpoint Status | Met |
Key Secondary Endpoints Status | Met |
Clinical Rating Scale | Montgomery–Åsberg Depression Rating Scale |
Rating Scale Abbreviation | MADRS |
Primary Reported Assessment | Week six |
Week Six Placebo-Adjusted Difference | 7.6 MADRS points |
Week Six Statistical Significance | p<0.0001 |
Week Twelve Placebo-Adjusted Difference | 7.0 MADRS points |
Earliest Reported Treatment Effect | Day two |
Treatment-Related Serious Adverse Events | Three |
Evidence Status | Company-reported topline Phase III results |
FDA Approval Granted | No |
Full Peer-Reviewed Publication | Not established in supplied summary |
Long-Term Safety Evidence | Further data remain important |
What Happened | Helus Pharma reported positive pivotal-stage efficacy findings for adjunctive HLP003 in major depressive disorder. |
Why It Matters | The results suggest a potentially important investigational treatment approach for patients with major depressive disorder. |
Clinical Significance | The reported trial met its primary and key secondary endpoints and demonstrated statistically significant improvements in depression severity scores. |
Safety Significance | Three treatment-related serious adverse events were reported, requiring consideration alongside efficacy findings. |
Evidence Clarification | Topline company results are not equivalent to independent confirmation or regulatory approval. |
Regulatory Clarification | HLP003 remains investigational. |
Key Takeaway | Helus Pharma reported positive Phase III HLP003 results in major depressive disorder, with additional regulatory and safety evaluation still required. |
What to Watch | Full clinical data, adverse-event characterisation, long-term follow-up, regulatory submissions and confirmatory evidence. |
Primary Source | Helus Pharma |
Primary Source URL | https://ir.helus.com/news-releases/news-release-details/helus-pharma-announces-positive-topline-results-phase-3-approach |
Submitted Source | GlobeNewswire |
Submitted Source URL | https://www.globenewswire.com/news-release/2026/11/16/3403358/0/en/helus-pharma-announces-positive-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder.html |
Relevant Date | 16 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com

Comments